Vtama in Psoriasis Patients Being Treated With Biologics.

NCT ID: NCT06103695

Last Updated: 2023-10-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-02-27
• Study Completion Date: 2023-10-18

Brief Summary

Open label study to assess 12 weeks of add-on VTAMA® (tapinarof) Cream, 1% QD in patients with ≥3% BSA who have received biologic therapy for at least 24 weeks.

Conditions

Psoriasis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Vtama

open label Vtama

Group Type: OTHER

Tapinarof

Intervention Type: DRUG

Add on Vtama (tapinarof) to biololgic therapy

Interventions

Tapinarof

Add on Vtama (tapinarof) to biololgic therapy

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or female adult ≥ 18 years of age;

2. Diagnosis of chronic plaque-type

3. Patient with ≥3% BSA

4. Patient has been treated with biologic for a minimum of 24 weeks

5. Able and willing to give written informed consent prior to performance of any study-related procedures.

Exclusion Criteria

1. ≤3% BSA

2. Patient not receiving biologic agent, or receiving biologic agent <24weeks

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Psoriasis Treatment Center of Central New Jersey

OTHER

Sponsor Role: lead

Responsible Party

Jerry Bagel

MD, MS

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Schweiger Derm Group

East Windsor, New Jersey, United States

Countries

United States

Other Identifiers

PTC10

Identifier Type: -

Identifier Source: org_study_id